2 weeks Ago
NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global hypoparathyroidism market size is estimated to grow by USD 474.9 million from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 7.6% during the forecast period. Increased awareness programs for thyroid treatment is driving market growth, with a trend towards growing use of inorganic growth strategies by vendors.
However, implementation of stringent regulations poses a challenge.Key market players include AdvaCare Pharma, Alkem Laboratories Ltd., Ascendis Pharma AS, AstraZeneca Plc, Cipla Inc.
, COSCIENS BIOPHARMA, Extend Biosciences Inc, F. Hoffmann La Roche Ltd., La Renon Healthcare Pvt.
Ltd., LLOYD Inc., Lupin Ltd.
, Merck and Co. Inc., Pfizer Inc.
, Sigmapharm Laboratories LLC, Sun Pharmaceutical Industries Ltd., VISEN Pharmaceuticals Co Ltd, and Wockhardt Ltd..
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver The global hypoparathyroidism market is experiencing a significant trend towards inorganic growth strategies, as companies look to expand their capabilities and market presence. AstraZeneca's acquisition of Amolyt Pharma in March 2024 is a prime example of this trend.
This strategic move adds the promising investigational therapeutic peptide , eneboparatide (AZP-3601), to AstraZeneca's portfolio. Eneboparatide's novel mechanism of action makes it a significant asset in addressing critical therapeutic goals for hypoparathyroidism. The acquisition not only strengthens AstraZeneca's product offerings but also underscores their commitment to the hypoparathyroidism market.
Inorganic growth strategies, such as mergers and acquisitions, enable firms to quickly acquire advanced technologies, innovative products, and specialized knowledge, accelerating their growth trajectory. This trend is crucial for the hypoparathyroidism market, as it advances treatment options and improves patient outcomes. With more companies adopting inorganic growth strategies, the industry is likely to see increased collaborative efforts and consolidated expertise, positively impacting the market during the forecast period.
Hypoparathyroidism is an endocrine disorder characterized by low levels of Parathyroid Hormone (PTH), leading to impaired calcium and phosphate metabolism. Serum phosphorus levels and albumin-corrected total calcium are essential markers for diagnosis. Hypoparathyroidism can result from thyroidectomy, genetic conditions, or autoimmune destruction.
Postoperative complications and transient hypoparathyroidism are common. Diagnosis involves assessing Plasma PTH, serum magnesium, and patient journey. Treatment goals include normalizing calcium and phosphate levels.
Dietary supplements and oral calcium supplements are common treatments. A drug recall for calcium supplements impacted the market. Emerging therapies, including calcitriol and hormonal therapy, have Fast Track Designation.
Epidemiology indicates approximately 1 in 2,500 people have hypoparathyroidism, with patient demographics skewed towards women. The treatment landscape includes Calcium Supplements and Vitamin D Analogues for idiopathic and hereditary hypoparathyroidism, and Hormonal Therapy for osteosarcoma-induced hypoparathyroidism. Patient screening is crucial to ensure early detection and effective management.
Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges The global hypoparathyroidism market is subject to stringent regulatory requirements, as evidenced by the extended review period for TransCon PTH, an investigational therapy by Ascendis Pharma A/S. This once-daily, long-acting prodrug aims to maintain physiological levels of parathyroid hormone (PTH) in adults with hypoparathyroidism. In December 2023 , Ascendis Pharma resubmitted the New Drug Application (NDA) following a Complete Response Letter (CRL) from the Food and Drug Administration (FDA), which necessitated additional information and amendments.
The FDA deemed this a major amendment, extending the review timeline under the Prescription Drug User Fee Act from May 14, 2024 , to August 14, 2024 . These regulatory hurdles pose challenges for market entrants, delaying new therapies and impacting patient access to innovative treatments. The uncertainty and extended review periods necessitate substantial investments in time and resources, straining smaller biotech firms and potential revenue streams.
Consequently, stringent regulations will negatively impact the global hypoparathyroidism market during the forecast period. The Hypoparathyroidism market faces unique challenges in the Treatment Market due to the complexities of managing an Endocrine Disorder characterized by low Parathyroid Hormone (PTH) levels, leading to imbalances in Calcium and Phosphate. Hypoparathyroidism can be Autoimmune, Hereditary, or Idiopathic, requiring various Treatment modalities such as Calcium Supplements, Vitamin D Analogues, and Hormonal Therapy.
Osteosarcoma and Hypocalcemia are potential complications. Patient Screening is crucial, but Drug Recalls and Hospitalization add to the challenges. Long-term Management involves Black Box Warnings, Medical Care Expenditure, and Personalized Medicines like Biologics.
The Biopharma Industry focuses on Clinical Trials for new Pharmaceutical solutions, including Parathyroid hormone, Vitamin D analogues, and Calcium supplements, available in Oral, Parenteral, and various forms for Hospitals, Homecare, Specialty Centers, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. Patient Awareness is essential, with a growing Patient Epidemiology and Pipeline Analysis in the Rare disease space. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This hypoparathyroidism market report extensively covers market segmentation by 1.
1 Parathyroid hormone 1.2 Vitamin D analogue 1.3 Calcium supplement 1.
4 Others 2.1 Hospital pharmacy 2.2 Retail pharmacy 2.
3 Online pharmacy 3.1 North America 3.2 Europe 3.
3 Asia 3.4 Rest of World (ROW) 1.1 Parathyroid hormone- The hypoparathyroidism market is driven by the development and approval of Parathyroid Hormone (PTH) therapies.
Despite a recent setback with the FDA, the European Commission approved YORVIPATH in November 2023 for chronic hypoparathyroidism. Hypoparathyroidism is a condition characterized by parathyroid gland dysfunction, leading to deficiency in parathyroid hormone, causing hypocalcemia, hyperphosphatemia, and neuromuscular irritability. Symptoms include muscle pain, spasms , twitching, seizures, and tetany.
Iatrogenic injury during head and neck surgeries is a common cause. PTH therapies are crucial for managing these symptoms and improving patient outcomes. The European approval of Yorvipath sets a precedent for other regions, potentially leading to increased adoption of PTH therapies globally.
Pharmaceutical companies invest in innovative solutions to address the unmet needs of hypoparathyroidism patients, driving market growth. In conclusion, regulatory approvals and new therapies are advancing the PTH segment within the hypoparathyroidism market, crucial for improving patient care and managing complex symptoms. The focus on PTH therapies will remain a key driver of growth and innovation in the industry.
Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of Parathyroid Hormone (PTH) leading to low calcium and high phosphate levels in the body. The treatment market for hypoparathyroidism includes calcium supplements, vitamin D analogues, and hormonal therapy. Calcium supplements help maintain normal calcium levels, while vitamin D analogues enhance calcium absorption.
Hormonal therapy involves the use of PTH or its analogues to restore normal calcium homeostasis. Calcitriol, a form of vitamin D, is also used to increase calcium absorption. Treatment for hypoparathyroidism can be oral, parenteral, or surgical, depending on the severity of the condition.
Hospitals, homecare, and specialty centers are common settings for the administration of these treatments. Thyroid surgery, particularly thyroidectomy, can cause hypoparathyroidism as a complication. The condition can be idiopathic, hereditary, or autoimmune in origin.
Diagnosis of hypoparathyroidism involves measuring serum calcium levels, serum phosphorus levels, albumin-corrected total calcium, and plasma parathyroid hormone levels. Serum magnesium levels may also be measured as low magnesium levels can exacerbate symptoms of hypoparathyroidism. Postoperative complications following thyroid surgery can also lead to hypoparathyroidism.
Genetic conditions and autoimmune destruction of the parathyroid glands are other causes of the disorder. Market Research Overview Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH), leading to low calcium and high phosphate levels in the body. The treatment market for hypoparathyroidism includes various options such as calcium supplements, vitamin D analogues, calcitriol, hormonal therapy, and biologics.
These medications aim to maintain normal calcium and phosphate levels, prevent hypocalcemia, and manage associated complications like osteosarcoma and postoperative complications following thyroidectomy. The hypoparathyroidism market landscape is diverse, with treatments available in various forms including oral, parenteral, and surgical options. Hospitals, homecare , specialty centers, hospital pharmacies, online pharmacies, and retail pharmacies are key channels for medication distribution.
Patient epidemiology and demographics play a significant role in the market, with an estimated 1 in 2,000 people affected by hypoparathyroidism. Diagnosis involves assessing serum calcium levels, serum phosphorus levels, albumin-corrected total calcium, plasma parathyroid hormone, and serum magnesium. The biopharma industry is focusing on personalized medicines, emerging therapies, and drug recalls to cater to the unique needs of hypoparathyroidism patients.
Clinical trials are ongoing to explore new treatment options, including Fast Track Designation for some therapies. Challenges in the market include the high cost of treatment, potential side effects, and the need for long-term management. A black box warning for certain medications highlights the importance of careful monitoring and patient education.
Patient awareness and advocacy efforts are crucial in managing hypoparathyroidism, with organizations promoting patient support, education, and research. The market is expected to grow due to the increasing prevalence of hypoparathyroidism, advances in treatment options, and the rising demand for personalized medicines. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Product Parathyroid Hormone Vitamin D Analogue Calcium Supplement Others Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company.
Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies.
This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.
com/ SOURCE Technavio.
